Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | PEPD | P12955 | 1/20 | 0.36 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
| ▸ | NOS2 | P35228 | 4/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5192188 | 1.00 | CA1 (0.40) | CA1CA2PEPDZDHHC7LTA4H | |
| SCHEMBL18109682 | 1.00 | CA1 (0.40) | CA1CA2PEPDZDHHC7LTA4H | |
| Hydrochloric Acid SCHEMBL15665036 | 0.98 | CA1 (0.39) | CA1CA2PEPDZDHHC7LTA4H | |
| Hydrochloric Acid SCHEMBL15665037 | 0.98 | CA1 (0.39) | CA1CA2PEPDZDHHC7LTA4H | |
| Trifluoroacetic Acid SCHEMBL29790595 | 0.93 | S1PR1 (0.36) | CA1CA2PEPDLTA4HNOS2 | |
| Trifluoroacetic Acid SCHEMBL31341361 | 0.93 | S1PR1 (0.36) | CA1CA2PEPDLTA4HNOS2 | |
| SCHEMBL1068024 | 0.92 | CA1 (0.38) | CA1CA2PEPDZDHHC7LTA4H | |
| SCHEMBL206673 | 0.92 | CA1 (0.38) | CA1CA2PEPDZDHHC7LTA4H | |
| Hydrochloric Acid SCHEMBL1068022 | 0.90 | NOS2 (0.39) | CA1CA2PEPDZDHHC7LTA4H | |
| Hydrochloric Acid SCHEMBL15666248 | 0.90 | NOS2 (0.39) | CA1CA2PEPDZDHHC7LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377100-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-09-29 | — | — | US | disclosed |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-07-14 | — | — | US | disclosed |
| WO-2020255038-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-24 | — | — | WO | disclosed |
| EP-3722297-A1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | Gilead Sciences, Inc. (US) | 2020-10-14 | — | — | EP | disclosed |
| EP-3321265-B1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10285990-B2 | Toll like receptor modulator compounds | GILEAD SCIENCES, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-3321265-A1 | 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR UTILISATION AS MODULATORS OF TOLL-LIKE RECEPTORS | Gilead Sciences, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3097102-B1 | TOLL-LIKE RECEPTOR MODULATING 4,6-DIAMINO-PYRIDO[3,2-D]PYRIMIDINE COMPOUNDS | GILEAD SCIENCES INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128425-A1 | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128425-A1 | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| WO-2014068095-A1 | CARBOXY-SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND THEIR USE AS SOLUBLE GUANYLATE CYCLASE STIMULANTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | WO | disclosed |
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-05-08 | — | — | US | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128386-A1 | Hydroxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | AADAC, TNNI3, PAH | CA1 3791/4885CA2 1557/4885PEPD 133/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | CA1 2481/4885CA2 658/4885PEPD 207/4885 |
| US-20140128425-A1 | Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use | TNNI3, CPS1, AADAC | CA1 2530/4885CA2 480/4885PEPD 54/4885 |
| US-10285990-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | CA1 4871/4885CA2 4092/4885PEPD 4069/4885 |
| US-20140128424-A1 | Hydroxy-substituted imidazo[1,2-a]-pyridinecarboxamides and their use | TNNI3, AADAC, TNNT2 | CA1 3822/4885CA2 1365/4885PEPD 109/4885 |
| US-20220218709-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | CA1 4871/4885CA2 4092/4885PEPD 4069/4885 |
| US-20190282576-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | CA1 4871/4885CA2 4092/4885PEPD 4069/4885 |
| US-12377100-B2 | Toll like receptor modulator compounds | TLR8, TLR3, TLR6 | CA1 4871/4885CA2 4092/4885PEPD 4069/4885 |
| US-20220305115-A1 | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND PYRIDOPYRIMIDINE DERIVATIVES | HAVCR2, ENTPD5, HMGB3 | CA1 4410/4885CA2 3460/4885PEPD 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.